Skip to main content
SpringerLink
Log in

Development of a Natural Health Product Active Surveillance Method in Outpatient Centers in Canada

  • Chapter
  • First Online:
Pharmacovigilance for Herbal and Traditional Medicines

Abstract

Natural health products (NHPs) are commonly used across the globe. Pre-market regulations for NHPs vary considerably by jurisdiction and little is known about clinically relevant interactions with other products. Enhanced pharmacovigilance is vital for a better understanding of NHP adverse events (AEs) and interactions with other NHPs and prescription drugs. Passive surveillance or spontaneous reporting systems are recognized for under-reporting and poor-quality AE reports, both of which are further exacerbated with regard to NHPs. A new approach to NHP AE active surveillance, including causality assessment, was developed and implemented. The main objective was to identify clinically relevant NHP adverse reactions (ARs). Methodology and major study results to date are discussed, as well as strengths, limitations, and future directions of this approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Health Canada (2020) Natural health products. https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription.html. Accessed 16 Apr 2020

  2. FDA (2015) FDA 101: dietary supplements. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements. Accessed 16 Apr 2020

  3. Australian Government Department of Health Complementary medicines. https://www.tga.gov.au/complementary-medicines. Accessed 16 Apr 2020

  4. European Medicines Agency Procedures for monograph and list entry establishment. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001149.jsp&mid=WC0b01ac0580033a9d. Accessed 13 Mar 2018

  5. Nahin RL, Barnes PM, Stussman BJ, Bloom B (2009) Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Rep 18:1–14

    Google Scholar 

  6. Xue CCL, Zhang AL, Lin V et al (2007) Complementary and alternative medicine use in Australia: a national population-based survey. J Altern Complement Med 13(6):643–650. https://doi.org/10.1089/acm.2006.6355

    Article  PubMed  Google Scholar 

  7. Corazza M, Borghi A, Lauriola M, Virgili A (2009) Use of topical herbal remedies and cosmetics: a questionnaire-based investigation in dermatology out-patients. J Eur Acad Dermatol Venereol 23(11):1298–1303. https://doi.org/10.1111/j.1468-3083.2009.03314.x

    Article  CAS  PubMed  Google Scholar 

  8. Hassan MAG (2014) Need to incorporate pharmacovigilance of herbal medicine to the curriculum. Natl J Physiol Pharm Pharmacol 4(2):99–100. https://doi.org/10.5455/njppp.2014.4.080620141

    Article  Google Scholar 

  9. WHO (2006) The safety of medicines in public health programmes: pharmacovigilance an essential tool

    Google Scholar 

  10. Black C, Tagiyeva-Milne N, Helms P, Moir D (2015) Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review. Br J Clin Pharmacol 80(4):844–854. https://doi.org/10.1111/bcp.12645

    Article  PubMed  PubMed Central  Google Scholar 

  11. Alvarez-Requejo A, Carvajal A, Begaud B et al (1998) Under-reporting of adverse drug reactions. Eur J Clin Pharmacol 54(6):483–488

    Article  CAS  Google Scholar 

  12. Jacobsson I, Jönsson AK, Gerdén B, Hägg S (2009) Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiol Drug Saf 18(11):1039–1047. https://doi.org/10.1002/pds.1818

    Article  CAS  PubMed  Google Scholar 

  13. Begum SS, Mansoor M, Sandeep A et al (2013) Tools to improve reporting of adverse drug reactions - a review. Int J Pharm Sci Rev Res 23(1):262–265

    Google Scholar 

  14. Barnes J (2003) Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: efficacy and safety. Br J Clin Pharmacol 55(4):331–340

    Article  CAS  Google Scholar 

  15. Hazell L, Shakir S (2006) Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5):385–396. https://doi.org/10.2165/00002018-200932010-00002

    Article  PubMed  Google Scholar 

  16. Barnes J, Mills SY, Abbot NC et al (1998) Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interview with 515 users of herbal remedies. Br J Clin Pharmacol 45(5):496–500. https://doi.org/10.1046/j.1365-2125.1998.00715.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Vickers KA, Jolly KB, Greenfield SM (2006) Herbal medicine: women’s views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med 6:40. https://doi.org/10.1186/1472-6882-6-40

    Article  PubMed  PubMed Central  Google Scholar 

  18. Charrois TL, Hill RL, Vu D et al (2007) Community identification of natural health product-drug interactions. Ann Pharmacother 41(7):1124–1129. https://doi.org/10.1345/aph.1H463

    Article  PubMed  Google Scholar 

  19. Government of Canada (2014) Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law): questions/answers. https://www.canada.ca/en/health-canada/services/drugs-health-products/legislation-guidelines/questions-answers-regarding-law-protecting-canadians-unsafe-drugs-act-vanessa-law.html. Accessed 1 Apr 2020

  20. Dal Pan GJ, Lindquist M, Gelperin K (2019) Postmarketing spontaneous pharmacovigilance reporting systems. In: Strom BL, Kimmel SE, Hennessy S (eds) Pharmacoepidemiology, 6th edn. Wiley-Blackwell, Hoboken, NJ, pp 165–201

    Chapter  Google Scholar 

  21. Reform FG, Care P (2007) The Erice Manifesto: for global reform of the safety of medicines in patient care. Drug Saf 30(3):187–190. https://doi.org/10.2165/00002018-200730030-00001

    Article  Google Scholar 

  22. Härmark L, Raine J, Leufkens H et al (2016) Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf 39(10):883–890. https://doi.org/10.1007/s40264-016-0441-x

    Article  PubMed  Google Scholar 

  23. Huang YL, Moon J, Segal JB (2014) A comparison of active adverse event surveillance systems worldwide. Drug Saf 37(8):581–596. https://doi.org/10.1007/s40264-014-0194-3

    Article  PubMed  PubMed Central  Google Scholar 

  24. FDA (2017) FDA’s sentinel initiative. https://www.fda.gov/Safety/FDAsSentinelInitiative/default.htm. Accessed 15 Mar 2018

  25. ICH (2004) E2E Pharmacovigilance Planning

    Google Scholar 

  26. Menniti-lppolito F, Raschetti R, Da Cas R et al (2000) Active monitoring of adverse drug reactions in children. Lancet 355(9215):1613–1614. https://doi.org/10.1016/S0140-6736(00)02219-4

    Article  Google Scholar 

  27. Tabali M, Jeschke E, Bockelbrink A et al (2009) Educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine. BMC Public Health 9:274. https://doi.org/10.1186/1471-2458-9-274

    Article  PubMed  PubMed Central  Google Scholar 

  28. Jose J, Rao PGM, Kamath MS, Jimmy B (2009) Drug safety reports on complementary and alternative medicines (ayurvedic and homeopathic medicines) by a spontaneous reporting program in a tertiary care hospital. J Altern Complement Med 15(7):793–797. https://doi.org/10.1089/acm.2008.0128

    Article  PubMed  Google Scholar 

  29. Necyk C, Tsuyuki RT, Boon H et al (2014) Pharmacy study of natural health product adverse reactions (SONAR): a cross-sectional study using active surveillance in community pharmacies to detect adverse events associated with natural health products and assess causality. BMJ Open 4(3):e003431. https://doi.org/10.1136/bmjopen-2013-003431

    Article  PubMed  PubMed Central  Google Scholar 

  30. Necyk C (2013) The Detection and Causality Assessment of Adverse Events Related to Natural Health Product Use in Community Pharmacies through the Implementation of Active Surveillance. Dissertation. University of Alberta

    Google Scholar 

  31. Vohra S, Cvijovic K, Boon H et al (2012) Study of natural health product adverse reactions (SONAR): active surveillance of adverse events following concurrent natural health product and prescription drug use in community pharmacies. PLoS One 7(9):e45196. https://doi.org/10.1371/journal.pone.0045196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Cvijovic K, Boon H, Jaeger W, Vohra S (2010) Pharmacists’ participation in research: a case of trying to find the time. Int J Pharm Pract 18:377–383. https://doi.org/10.1111/j.2042-7174.2010.00067.x

    Article  PubMed  Google Scholar 

  33. Necyk C, Khamba B, Chue P et al (2016) Study of natural health product–drug adverse reactions (S.O.N.A.R.) in patients seeking mental health services. Curr Med Res Opin 32(8):1335–1343. https://doi.org/10.1185/03007995.2016.1174109

    Article  PubMed  Google Scholar 

  34. Jordan SA, Cunningham DG, Marles RJ (2010) Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol 243(2):198–216. https://doi.org/10.1016/j.taap.2009.12.005

    Article  CAS  PubMed  Google Scholar 

  35. European Medicines Agency (1995) Note for guidance on clinical safety data management: definitions and standards for expedited reporting (CPMP/ICH/377/95). ICH Topic E 2 A clinical safety data management: definitions and standards for expedited report. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf. Accessed 16 Apr 2020

  36. Théophile H, André M, Arimone Y et al (2012) An updated method improved the assessment of adverse drug reaction in routine pharmacovigilance. J Clin Epidemiol 65(10):1069–1077. https://doi.org/10.1016/j.jclinepi.2012.04.015

    Article  PubMed  Google Scholar 

  37. Agbabiaka TB, Savovi J, Ernst E (2008) Methods for causality assessment of a systematic review. Drug Saf 31(1):21–37

    Article  Google Scholar 

  38. Khan LM, Al-Harthi SE, Osman AMM et al (2016) Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm J 24(4):485–493. https://doi.org/10.1016/j.jsps.2015.01.010

    Article  PubMed  Google Scholar 

  39. Jones JK, Begaud B, Kingery E (2020) Assessing causation from case reports. In: Strom BL, Kimmel SE, Hennessy S (eds) Pharmacoepidemiology, 6th edn. Wiley-Blackwell, Hoboken, NJ, pp 723–745

    Google Scholar 

  40. Macedo AF, Marques FB, Ribeiro CF (2006) Can decisional algorithms replace global introspection in the individual causality assessment of spontaneously reported ADRs? Drug Saf 29:697–702. https://doi.org/10.2165/00002018-200629080-00006

    Article  PubMed  Google Scholar 

  41. Barnes J (2003) Pharmacovigilance of herbal medicines: a UK Perspective. Drug Saf 26(12):829–851. https://doi.org/10.2165/00002018-200326120-00001

    Article  PubMed  Google Scholar 

  42. The Uppsala Monitoring Centre (2005) The use of the WHO-UMC system for standardized case causality assessment

    Google Scholar 

  43. Naranjo C, Busto U, Sellers M et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245

    Article  CAS  Google Scholar 

  44. Horn JR, Hansten PD, Chan L-N (2007) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41(4):674–680. https://doi.org/10.1345/aph.1H423

    Article  PubMed  Google Scholar 

  45. Fedak KM, Bernal A, Capshaw ZA et al (2015) Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol 12:14. https://doi.org/10.1186/s12982-015-0037-4

    Article  PubMed  PubMed Central  Google Scholar 

  46. Nelson MH, Cobb SE, Shelton J (2002) Variations in parthenolide content and daily dose of feverfew products. Am J Heal Pharm 59(16):1527–1531. https://doi.org/10.1093/ajhp/59.16.1527

    Article  CAS  Google Scholar 

  47. Garrard J, Harms S, Eberly LE, Matiak A (2003) Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med 163(19):2290–2295. https://doi.org/10.1001/archinte.163.19.2290

    Article  PubMed  Google Scholar 

  48. Perharic L, Shaw D, Colbridge M et al (1994) Toxicological problems resulting from exposure to traditional remedies and food supplements. Drug Saf 11:284–294. https://doi.org/10.2165/00002018-199411040-00006

    Article  CAS  PubMed  Google Scholar 

  49. Gurley BJ, Gardner SF, Hubbard MA (2000) Content versus label claims in ephedra-containing dietary supplements. Am J Heal Pharm 57(10):963–969. https://doi.org/10.1093/ajhp/57.10.963

    Article  CAS  Google Scholar 

  50. Ernst E (2000) Herb-drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol 56:523–524. https://doi.org/10.1007/s002280000194

    Article  CAS  PubMed  Google Scholar 

  51. Cvijovic K, Boon H, Jaeger W, Vohra S (2011) Polypharmacy, multiple natural health products and hepatotoxicity. CMAJ 183(14):e1085–e1089

    Article  Google Scholar 

  52. Miller MF, Bellizzi KM, Sufian M et al (2008) Dietary supplement use in individuals living with cancer and other chronic conditions: a population-based study. J Am Diet Assoc 108(3):483–494. https://doi.org/10.1016/j.jada.2007.12.005

    Article  PubMed  Google Scholar 

  53. Hazra M, Uchida H, Sproule B et al (2011) Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry Clin Neurosci 65:676–678. https://doi.org/10.1111/j.1440-1819.2011.02280.x

    Article  PubMed  Google Scholar 

  54. Poon SH, Sim K, Sum MY et al (2012) Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar Disord 14:573–584. https://doi.org/10.1111/j.1399-5618.2012.01042.x

    Article  PubMed  Google Scholar 

  55. Manolopoulos VG, Ragia G, Alevizopoulos G (2012) Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics. Drug Metabol Drug Interact 27(1):19–31. https://doi.org/10.1515/dmdi-2011-0033

    Article  CAS  PubMed  Google Scholar 

  56. Kruszkowksi M, Malti T, Modestin J (2003) Use of alternative therapy by psychiatric inpatients. Int J Psychiatry Clin Pract 7(3):161–166

    Article  Google Scholar 

  57. Gitlin M, Frye MA (2012) Maintenance therapies in bipolar disorders. Bipolar Disord 14:51–65. https://doi.org/10.1111/j.1399-5618.2012.00992.x

    Article  PubMed  Google Scholar 

  58. Brzakoviać BB, Vezmar Kovačević SD, Vučiaćević KM et al (2012) Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. J Clin Pharm Ther 37(6):693–697. https://doi.org/10.1111/j.1365-2710.2012.01351.x

    Article  CAS  Google Scholar 

  59. Crepeau AZ, Moseley BD, Wirrell EC (2012) Specific safety and tolerability considerations in the use of anticonvulsant medications in children. Drug Healthc Patient Saf 4:39–54. https://doi.org/10.2147/DHPS.S28821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Zeller T, Muenstedt K, Stoll C et al (2013) Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol 139:357–365. https://doi.org/10.1007/s00432-012-1336-6

    Article  CAS  PubMed  Google Scholar 

  61. Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4. https://doi.org/10.1186/1472-6874-7-4

    Article  PubMed  PubMed Central  Google Scholar 

  62. Greenlee H, Neugut AI, Falci L et al (2016) Association between complementary and alternative medicine use and breast cancer chemotherapy initiation the Breast Cancer Quality of Care (BQUAL) Study. JAMA Oncol 2(9):1170–1176. https://doi.org/10.1001/jamaoncol.2016.0685

    Article  PubMed  PubMed Central  Google Scholar 

  63. Lee AH, Ingraham SE, Kopp M et al (2006) The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital. Am J Clin Oncol 29(2):178–182. https://doi.org/10.1097/01.coc.0000209369.44100.25

    Article  CAS  PubMed  Google Scholar 

  64. Wilkinson JM, Stevens MJ (2014) Use of complementary and alternative medical therapies (CAM) by patients attending a regional comprehensive cancer care centre. J Complement Integr Med 11(2):139–145. https://doi.org/10.1515/jcim-2013-0048

    Article  PubMed  Google Scholar 

  65. Bonacchi A, Fazzi L, Toccafondi A et al (2014) Use and perceived benefits of complementary therapies by cancer patients receiving conventional treatment in Italy. J Pain Symptom Manag 47(1):26–34. https://doi.org/10.1016/j.jpainsymman.2013.03.014

    Article  Google Scholar 

  66. Bishop FL, Prescott P, Chan YK et al (2010) Prevalence of complementary medicine use in pediatric cancer: a systematic review. Pediatrics 125(4):768–776. https://doi.org/10.1542/peds.2009-1775

    Article  PubMed  Google Scholar 

  67. Balneaves LG, Weeks L, Seely D (2008) Patient decision-making about complementary and alternative medicine in cancer management: context and process. Curr Oncol 15(Suppl. 2):s94–s100. https://doi.org/10.3747/co.v15i0.280

    Article  PubMed  PubMed Central  Google Scholar 

  68. Alnaim L (2007) Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Pract 13(4):207–221. https://doi.org/10.1177/1078155207081133

    Article  CAS  PubMed  Google Scholar 

  69. Blix HS, Viktil KK, Moger TA, Reikvam A (2010) Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharm Pract (Granada) 8(1):50–55. https://doi.org/10.4321/S1886-36552010000100006

    Article  PubMed Central  Google Scholar 

  70. Statistics Canada (2015) Canadian cancer statistics. https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2015-EN.pdf?la=en. Accessed 16 Apr 2020

  71. Roberts D, Wilson C, Todd C et al (2013) Complementary therapies in cancer: patients’ views on their purposes and value pre and post receipt of complementary therapy - a multi-centre case study. Eur J Integr Med 5(5):443–449. https://doi.org/10.1016/j.eujim.2013.06.005

    Article  Google Scholar 

  72. Jean D, Cyr C (2007) Use of complementary and alternative medicine in a general pediatric clinic. Pediatrics 120(1):e138–e141. https://doi.org/10.1542/peds.2006-3105

    Article  PubMed  Google Scholar 

  73. Ang JY, Ray-Mazumder S, Nachman SA et al (2005) Use of complementary and alternative medicine by parents of children with HIV infection and asthma and well children. South Med J 98(9):869–875. https://doi.org/10.1097/01.smj.0000173089.51284.69

    Article  PubMed  Google Scholar 

  74. Piscitelli SC, Burstein AH, Chaitt D et al (2000) Indinavir concentrations and St John’s wort. Lancet 355(9203):547–548. https://doi.org/10.1016/S0140-6736(99)05712-8

    Article  CAS  PubMed  Google Scholar 

  75. Sussman E (2002) Garlic supplements can impede HIV medication. AIDS 16(9):N5

    Article  Google Scholar 

  76. Weigman D-J, Brinkman K, Franssen EJF (2009) Interaction of ginkgo biloba with efavirenz. AIDS 23(9):1184–1185. https://doi.org/10.1097/QAD.0b013e32832c412b

    Article  Google Scholar 

  77. Light TD, Light JA (2003) Acute renal transplant rejection possibly related to herbal medications. Am J Transplant 3:1608–1609. https://doi.org/10.1046/j.1600-6135.2003.00270.x

    Article  PubMed  Google Scholar 

  78. Bolley R, Zülke C, Kammerl M et al (2002) Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John’s wort. Transplantation 73(6):1009

    Article  Google Scholar 

  79. Dowling TC (2002) Drug metabolism considerations in patients with chronic kidney disease. J Pharm Pract 15(5):419–427. https://doi.org/10.1177/089719002237265

    Article  Google Scholar 

  80. Anzenbacher P, Zanger UM (eds) (2012) Metabolism of drugs and other xenobiotics. Wiley-VCH

    Google Scholar 

  81. Dahl NV (2001) Herbs and supplements in dialysis patients: panacea or poison? Semin Dial 14:186–192. https://doi.org/10.1046/j.1525-139X.2001.00051.x

    Article  CAS  PubMed  Google Scholar 

  82. Kutt A, Girard L, Necyk C et al (2016) Natural health product – drug interaction tool: a scoping review. Can Pharm J 149(2):75–82. https://doi.org/10.1177/1715163516629156

    Article  Google Scholar 

  83. Cvijovic K, Boon H, Barnes J et al (2009) A tool for rapid identification of potential herbal medicine – drug interactions. Can Pharm J 142(5):224–247. https://doi.org/10.3821/1913-701X-142.5.224

    Article  Google Scholar 

  84. Accreditation Canada, the Canadian Institute for Health Information, the Canadian Patient Safety Institute, the Institute for Safe Medication Practices Canada (2012) Medication reconciliation in Canada: raising the bar - progress to date and the course ahead. https://www.ismp-canada.org/download/MedRec/20121101MedRecCanadaENG.pdf. Accessed 16 Apr 2020

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada

    Morgan Bharadia & Candace Necyk

  2. Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

    Morgan Bharadia

  3. Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

    Sunita Vohra

  4. Department of Psychiatry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

    Sunita Vohra

Authors
  1. Morgan Bharadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Candace Necyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sunita Vohra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Morgan Bharadia .

Editor information

Editors and Affiliations

  1. School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

    Joanne Barnes

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bharadia, M., Necyk, C., Vohra, S. (2022). Development of a Natural Health Product Active Surveillance Method in Outpatient Centers in Canada. In: Barnes, J. (eds) Pharmacovigilance for Herbal and Traditional Medicines. Adis, Cham. https://doi.org/10.1007/978-3-031-07275-8_12

Download citation

Publish with us

Policies and ethics

Search

Navigation